JP2016128513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128513A5 JP2016128513A5 JP2016068623A JP2016068623A JP2016128513A5 JP 2016128513 A5 JP2016128513 A5 JP 2016128513A5 JP 2016068623 A JP2016068623 A JP 2016068623A JP 2016068623 A JP2016068623 A JP 2016068623A JP 2016128513 A5 JP2016128513 A5 JP 2016128513A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- positions
- use according
- hbv
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161442204P | 2011-02-12 | 2011-02-12 | |
| US61/442,204 | 2011-02-12 | ||
| US201161496945P | 2011-06-14 | 2011-06-14 | |
| US61/496,945 | 2011-06-14 | ||
| US201161507361P | 2011-07-13 | 2011-07-13 | |
| US61/507,361 | 2011-07-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015025534A Division JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017043689A Division JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128513A JP2016128513A (ja) | 2016-07-14 |
| JP2016128513A5 true JP2016128513A5 (enExample) | 2016-12-22 |
| JP6109989B2 JP6109989B2 (ja) | 2017-04-05 |
Family
ID=46638950
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553534A Active JP5745102B2 (ja) | 2011-02-12 | 2012-02-09 | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| JP2015025534A Active JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2016068623A Active JP6109989B2 (ja) | 2011-02-12 | 2016-03-30 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2017043689A Pending JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553534A Active JP5745102B2 (ja) | 2011-02-12 | 2012-02-09 | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| JP2015025534A Active JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017043689A Pending JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8877205B2 (enExample) |
| EP (2) | EP3266464A3 (enExample) |
| JP (4) | JP5745102B2 (enExample) |
| KR (1) | KR102026840B1 (enExample) |
| CN (1) | CN103476426B (enExample) |
| AP (1) | AP2013007110A0 (enExample) |
| AU (2) | AU2012214394B2 (enExample) |
| BR (1) | BR112013020425A2 (enExample) |
| CA (1) | CA2827150C (enExample) |
| CL (1) | CL2013002334A1 (enExample) |
| CO (1) | CO6791572A2 (enExample) |
| CR (1) | CR20130424A (enExample) |
| EA (1) | EA028659B1 (enExample) |
| EC (1) | ECSP13012862A (enExample) |
| ES (1) | ES2643389T3 (enExample) |
| HK (1) | HK1248120A1 (enExample) |
| IL (1) | IL227900B (enExample) |
| MA (1) | MA34956B1 (enExample) |
| PE (1) | PE20140844A1 (enExample) |
| PH (1) | PH12013501683A1 (enExample) |
| SG (1) | SG192285A1 (enExample) |
| TW (1) | TWI504608B (enExample) |
| UA (1) | UA112859C2 (enExample) |
| WO (1) | WO2012109404A1 (enExample) |
| ZA (1) | ZA201306481B (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| PL2672992T3 (pl) | 2011-02-11 | 2020-11-02 | The Trustees Of The University Of Pennsylvania | Cząsteczka kwasu nukleinowego kodująca białko rdzeniowe wirusa zapalenia wątroby typu B i szczepionka je zawierająca |
| US9238679B2 (en) * | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
| EP3266464A3 (en) | 2011-02-12 | 2018-03-14 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis b infection |
| KR102046449B1 (ko) | 2011-03-17 | 2019-11-19 | 글로브이뮨 | 효모-브라큐리 면역요법 조성물 |
| EA030381B1 (ru) | 2011-06-14 | 2018-07-31 | Глоубиммьюн, Инк. | Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта |
| CA2844500C (en) | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
| US9653272B2 (en) | 2012-06-26 | 2017-05-16 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| CN111499722B (zh) | 2012-11-12 | 2024-08-23 | 海德堡吕布莱希特-卡尔斯大学 | 用于治疗肝脏疾病和心血管疾病的脂肽 |
| MX374829B (es) | 2013-03-19 | 2025-03-06 | Globeimmune Inc | Composición a base de levadura para usarse para tratar cordoma. |
| US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| WO2015031778A2 (en) | 2013-08-30 | 2015-03-05 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| CN113419058B (zh) * | 2014-04-11 | 2025-04-01 | 全球免疫股份有限公司 | 基于酵母的免疫疗法和i型干扰素敏感性 |
| CN107001429B (zh) * | 2014-11-28 | 2022-01-04 | 赛特瑞恩股份有限公司 | 乙型肝炎病毒表面抗原的表位及与其特异性结合以中和乙型肝炎病毒的结合分子 |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| PL3097102T3 (pl) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego |
| WO2017023840A1 (en) | 2015-08-03 | 2017-02-09 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| CN115948467A (zh) * | 2015-11-04 | 2023-04-11 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| CN116732101A (zh) * | 2016-01-12 | 2023-09-12 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 用于治疗hbv的手段和方法 |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EP3276006A1 (en) * | 2016-07-27 | 2018-01-31 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| KR102268448B1 (ko) | 2016-09-02 | 2021-06-22 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| CN106421774B (zh) * | 2016-09-08 | 2019-05-28 | 中国科学院生物物理研究所 | PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途 |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| TWI868958B (zh) | 2017-01-31 | 2025-01-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| US11471527B2 (en) | 2017-06-05 | 2022-10-18 | Beacle Inc. | Virus-like particles including HBs-L antigen protein for causing immune response against HBV |
| JP6934562B2 (ja) | 2017-08-22 | 2021-09-15 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| CA3085492A1 (en) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |
| ES2963179T3 (es) * | 2017-12-19 | 2024-03-25 | Janssen Sciences Ireland Unlimited Co | Vacunas contra el virus de la hepatitis b (VHB) y usos de las mismas |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| JP7581048B2 (ja) | 2018-03-06 | 2024-11-12 | プレシゲン，インコーポレイテッド | ヒトパピローマウイルスワクチンおよびその使用 |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| EP3793576A4 (en) | 2018-05-15 | 2022-04-06 | Globeimmune, Inc. | Lysates of recombinant yeast for inducing cellular immune responses |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| JP7049519B2 (ja) | 2018-07-06 | 2022-04-06 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| WO2020254876A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| PH12022550490A1 (en) | 2019-08-29 | 2023-02-06 | Triad Nat Security Llc | Hepatitis b virus vaccines |
| JP7494199B2 (ja) * | 2019-09-27 | 2024-06-03 | 富士レビオ株式会社 | Ｂ型肝炎ウイルスコア関連抗原のイムノアッセイ及びそのためのキット |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| AU2021205936A1 (en) * | 2020-01-09 | 2022-07-21 | The Wistar Institute | Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| WO2022006146A1 (en) * | 2020-06-29 | 2022-01-06 | The Trustees Of Columbia University In The City Of New York | Yeast-based vaccines |
| JP7712352B2 (ja) | 2020-08-07 | 2025-07-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
| WO2024220982A1 (en) * | 2023-04-21 | 2024-10-24 | The Wistar Institute Of Anatomy And Biology | Compositions comprising aptamers and methods of modulating the immune response using the same |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5164485A (en) * | 1985-08-20 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Modified hepatitis B virus surface antigen P31 and production thereof |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| US6306625B1 (en) * | 1988-12-30 | 2001-10-23 | Smithkline Beecham Biologicals, Sa | Method for obtaining expression of mixed polypeptide particles in yeast |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| WO1994012617A1 (en) * | 1992-11-25 | 1994-06-09 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| JP3713900B2 (ja) | 1996-07-19 | 2005-11-09 | ソニー株式会社 | 負極材料及びこれを用いた非水電解液二次電池 |
| NZ506245A (en) * | 1998-02-12 | 2003-08-29 | Immune Complex Corp | Strategically modified hepatitis b core proteins and their derivatives |
| AU2358201A (en) * | 1999-12-03 | 2001-06-12 | Innogenetics N.V. | New hbv sequences |
| GB0216074D0 (en) * | 2002-07-11 | 2002-08-21 | Weatherford Lamb | Improving collapse resistance of tubing |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| US8153414B2 (en) | 2000-04-06 | 2012-04-10 | Allertein Therapeutics, Llc | Microbial delivery system |
| WO2002039951A2 (en) | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| CN1171636C (zh) * | 2001-06-06 | 2004-10-20 | 中国人民解放军第二军医大学 | 一种乙型肝炎dna疫苗 |
| US8029803B2 (en) * | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| KR101241272B1 (ko) | 2002-12-16 | 2013-03-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 면역 요법으로서의 효모계 백신 |
| EP1609107A4 (en) * | 2003-03-28 | 2006-08-30 | Idm Pharma Inc | METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS |
| DE10339927A1 (de) | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
| JP2008516610A (ja) | 2004-10-18 | 2008-05-22 | グローブイミューン，インコーポレイテッド | 酵母を用いた慢性ｃ型肝炎感染の治療 |
| SG163572A1 (en) | 2005-07-11 | 2010-08-30 | Globeimmune Inc | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| CA2647102A1 (en) | 2006-03-27 | 2007-11-22 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
| KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| CA2676783C (en) | 2007-02-02 | 2016-04-05 | Globeimmune, Inc. | Improved methods for producing yeast-based vaccines |
| CN101036784B (zh) * | 2007-03-09 | 2010-11-10 | 中国人民解放军第二军医大学 | 一种乙型肝炎治疗性细胞毒性t细胞表位疫苗及其制备方法 |
| BRPI0809247A2 (pt) | 2007-03-19 | 2014-09-09 | Globeimmune Inc | Composições e métodos para a ablação do escape mutacional de terapias marcadas para câncer. |
| WO2010033841A1 (en) | 2008-09-19 | 2010-03-25 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis c virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| EP3320915A1 (en) | 2009-04-17 | 2018-05-16 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| WO2011032119A1 (en) | 2009-09-14 | 2011-03-17 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
| JP2013522302A (ja) | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| EP3266464A3 (en) * | 2011-02-12 | 2018-03-14 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis b infection |
| KR102046449B1 (ko) | 2011-03-17 | 2019-11-19 | 글로브이뮨 | 효모-브라큐리 면역요법 조성물 |
| EA030381B1 (ru) | 2011-06-14 | 2018-07-31 | Глоубиммьюн, Инк. | Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта |
| CA2844500C (en) | 2011-08-17 | 2022-05-10 | Globeimmune, Inc. | Yeast-muc1 immunotherapeutic compositions and uses thereof |
-
2012
- 2012-02-09 EP EP17175311.4A patent/EP3266464A3/en not_active Withdrawn
- 2012-02-09 MA MA36222A patent/MA34956B1/fr unknown
- 2012-02-09 KR KR1020137024018A patent/KR102026840B1/ko active Active
- 2012-02-09 PE PE2013001865A patent/PE20140844A1/es not_active Application Discontinuation
- 2012-02-09 ES ES12744328.1T patent/ES2643389T3/es active Active
- 2012-02-09 CA CA2827150A patent/CA2827150C/en active Active
- 2012-02-09 EA EA201391170A patent/EA028659B1/ru not_active IP Right Cessation
- 2012-02-09 PH PH1/2013/501683A patent/PH12013501683A1/en unknown
- 2012-02-09 WO PCT/US2012/024409 patent/WO2012109404A1/en not_active Ceased
- 2012-02-09 AU AU2012214394A patent/AU2012214394B2/en active Active
- 2012-02-09 CN CN201280018222.5A patent/CN103476426B/zh active Active
- 2012-02-09 AP AP2013007110A patent/AP2013007110A0/xx unknown
- 2012-02-09 BR BR112013020425A patent/BR112013020425A2/pt not_active IP Right Cessation
- 2012-02-09 EP EP12744328.1A patent/EP2672991B1/en active Active
- 2012-02-09 SG SG2013060777A patent/SG192285A1/en unknown
- 2012-02-09 US US13/984,888 patent/US8877205B2/en active Active
- 2012-02-09 JP JP2013553534A patent/JP5745102B2/ja active Active
- 2012-02-10 TW TW101104436A patent/TWI504608B/zh active
- 2012-09-02 UA UAA201310911A patent/UA112859C2/uk unknown
-
2013
- 2013-03-13 US US13/798,837 patent/US8722054B2/en active Active
- 2013-08-12 CL CL2013002334A patent/CL2013002334A1/es unknown
- 2013-08-28 ZA ZA2013/06481A patent/ZA201306481B/en unknown
- 2013-08-30 EC ECSP13012862 patent/ECSP13012862A/es unknown
- 2013-08-31 CR CR20130424A patent/CR20130424A/es unknown
- 2013-09-12 CO CO13216900A patent/CO6791572A2/es unknown
- 2013-09-29 IL IL227900A patent/IL227900B/en active IP Right Grant
-
2014
- 2014-02-19 US US14/184,481 patent/US8961988B2/en active Active
- 2014-09-23 US US14/494,235 patent/US9290547B2/en active Active
-
2015
- 2015-01-07 US US14/591,592 patent/US9428556B2/en active Active
- 2015-02-12 JP JP2015025534A patent/JP5911983B2/ja active Active
-
2016
- 2016-03-30 JP JP2016068623A patent/JP6109989B2/ja active Active
- 2016-07-18 US US15/212,930 patent/US9943591B2/en active Active
- 2016-11-10 AU AU2016256751A patent/AU2016256751B2/en active Active
-
2017
- 2017-03-08 JP JP2017043689A patent/JP2017105834A/ja active Pending
-
2018
- 2018-03-01 US US15/909,112 patent/US10441650B2/en active Active
- 2018-06-13 HK HK18107680.0A patent/HK1248120A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016128513A5 (enExample) | ||
| JP2015096557A5 (enExample) | ||
| Spyrou et al. | Hepatitis B: current status of therapy and future therapies | |
| Kim et al. | Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus | |
| Liang et al. | Present and future therapies of hepatitis B: from discovery to cure | |
| Paladini et al. | The worldwide impact of vaccination on the control and protection of viral hepatitis B | |
| CN110612118B (zh) | 用于引起针对hbv的免疫应答的病毒样粒子 | |
| Li et al. | Research progress of therapeutic vaccines for treating chronic hepatitis B | |
| RU2749730C1 (ru) | Бисдиазабицикло-соединение для лечения и/или профилактики заболеваний или расстройств, связанных с вирусом гепатита | |
| JP2014507144A5 (ja) | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 | |
| JP2014527404A5 (enExample) | ||
| JP2014523878A5 (enExample) | ||
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| JP2016505589A5 (enExample) | ||
| JP2017515508A5 (enExample) | ||
| Yoshida et al. | Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study | |
| Karimkhanilouyi et al. | Nucleic acid vaccines for hepatitis B and C virus | |
| Jilg | Novel hepatitis B vaccines | |
| Tang et al. | Advances in new antivirals for chronic hepatitis B | |
| EP3437654B1 (en) | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus | |
| Pentón-Arias et al. | Cuban prophylactic and therapeutic vaccines for controlling hepatitis B | |
| JP2014534262A5 (enExample) | ||
| CN106421774A (zh) | PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途 | |
| Wen et al. | Vaccine therapies for chronic hepatitis B: can we go further? | |
| Hong et al. | Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice |